Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival

British Journal of Cancer

Volumn 100, Issue 7, 2009, Pages 1095-1102

  Herath, N I ^a   Doecke, J ^a   Spanevello, M D ^a   Leggett, B A ^b,c   Boyd, A W ^a,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Royal Brisbane and Womens Hospital Research Foundation   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Colorectal cancer; Downregulation; EphA1; Methylation; Quantitative PCR

Indexed keywords

EPHRIN RECEPTOR A1; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; COLON; COLORECTAL CANCER; CPG ISLAND; DISEASE COURSE; DISEASE MARKER; DOWN REGULATION; EPIGENETICS; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

AZACITIDINE; CELL LINE, TUMOR; COLON; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RECEPTOR, EPHA1;

EID: 63949086165     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604970     Document Type: Article

References (34)

1. Adams RH (2002) Vascular patterning by Eph receptor tyrosine kinases and ephrins. Sem Cell Dev Biol 13: 55-60
2. Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espin E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S, Arango D (2005) Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65: 10170-10173
3. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435: 1126-1130
4. Batlle E, Henderson JT, Beghtel H, van de Born MM, Sancho E, Huls G, Meeldjik J, Robertson J, van de Wetering M, Pawson T, Clevers H (2002) Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111: 251-263
5. Berclaz G, Flutsch B, Altermatt HJ, Rohrbach V, Djonov V, Ziemiecki A, Dreher E, Andrew AC (2002) Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep 9: 985-989
6. Brantley-Sieders D, Schmidt S, Parker M, Chen J (2004) Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 10: 3431-3442
7. Boyd AW, Lackmann M (2001) Signals from Eph and ephrin proteins: a developmental tool kit. Sci STKE 200: RE20-RE26
8. Coulthard MG, Lickliter JD, Subanesan N, Chen K, Webb GC, Lowry AJ, Koblar S, Bottema CD, Boyd AW (2001) Characterization of the Epha1 receptor tyrosine kinase: expression in epithelial tissues. Growth Factors 18: 303-317
9. Dodelet VC, Pasquale EB (2000) Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19: 5614-5619
10. Dottori M, Down M, Huettmann A, Fitzpatrick DR, Boyd AW (1999) DNA methylation regulates expression in hematopoietic tumor cells. Blood 94: 2477- 2486
11. Gale NW, Holland SJ, Valenzuela DM, Flenniken A, Pan L, Ryan TE, Henkemeyer M, Strebhardt K, Hirai H, Wilkinson DG, Pawson T, Davis S, Yancopoulos GD (1996) Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17: 9-19
12. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196: 261-282
13. Guo DL, Zhang J, Yuen ST, Tsui WY, Chan AS, Ho C, Ji J, Leung SY, Chen X (2006) Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumors. Carcinogenesis 27: 454-464
14. Hafner C, Becker B, Landthaler M, Vogt T (2006) Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol 19: 1369-1377
15. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T (2004) Differential gene expression of Eph receptors and Ephrins in benign human tissues and cancers. Clin Chem 50: 490-499
16. Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F (1987) A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238: 1717- 1720
17. Kao HW, Chen HC, Wu CW, Lin WC (2003) Tyrosine-kinase expression profiles in human gastric cancer cell lines and their modulations with retinoic acids. Br J Cancer 88: 1058- 1064
18. Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Li ZY, Shimamura T, Kobayashi T, Maruyama K, Nakamura T, Arai H, Kajimura M, Hanai H, Tanaka M, Sugimura H (2004) Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 95: 136-141
19. Kataoka H, Tanaka M, Kanamori M, Yoshii S, Ihara M, Wang YJ, Song JP, Li ZY, Arai H, Otsuki Y, Kobayashi T, Konno H, Hanai H, Sugimura H (2002) Expression profile of EFNB1, EFNB2, two ligands of EPHB2 in human gastric cancer. J Cancer Res Clin Oncol 128: 343-348
20. Landen CN, Kinch MS, Sood AK (2005) EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 9: 1179-1187
21. Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD, Ellis LM (2002) Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94: 934-939
22. Liu W, Jung YD, Ahmad SA, McCarthy MF, Stoeltzing O, Reinmuth N, Fan F, Ellis LM (2004) Effects of over expression of ephrin-B2 on tumor growth in human colorectal cancer. Br J Cancer 90: 1620- 1626
23. Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L (2005) EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers. Clin Cancer Res 11: 6450- 6458
24. Mao W, Luis E, Ross S, Silva J, Tan C, Crowley C, Chui C, Franz G, Senter P, Koeppen H, Polakis P (2004) EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 64: 781-788
25. Maru Y, Hirai H, Takaku F (1990) Overexpression confers an oncogenic potential upon the eph gene. Oncogene 5: 445-447
26. Nakamoto M, Bergemann AD (2002) Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59: 58-67
27. Robinson D, He F, Pretlow T, Kung HJ (1996) A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 93: 5958-5962
28. Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, Asao T, Kuwano H (2004) Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 11: 605-611
29. Sancho E, Batlle E, Clevers H, Sawai Y, Tamura S, Fukui K, Ito N, Imanaka K, Saeki A, Sakuda S, Kiso S, Matsuzawa Y, Hafner C, Bataille F, Meyer S, Becker B, Roesch AL, Landthaler M, Vogt T (2003) Live and let die in the intestinal epithelium. Curr Opin Cell Biol 15: 763-770
30. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE (2001) Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2: 15
31. Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, Brechbiel M, Boyd A, Scott AM, Lackmann M (2005) Concurrent binding of anti-EphA3 antibody and ephrin A5 amplifies EphA3 signalling and downstream responses: potential as EphA3-specific tumor targeting reagents. Cancer Res 65: 6745-6754
32. Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, Maruyama K, Isogaki J, Kanaoka S, Ihara M, Tanaka M, Kanamori M, Nakamura T, Shinmura K, Sugimura H (2005) Down regulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 24: 5637-5647
33. Wilkinson DG (2003) How attraction turns to repulsion. Nat Cell Biol 5: 851-853
34. Worm J, Aggerholm A, Guldberg P (2001) In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem 47: 1183- 1189